Listed Indian arm of GSK plc, selling branded prescription medicines and vaccines in the Indian market.
Listed Indian arm of GSK plc, selling branded prescription medicines and vaccines in the Indian market.
Sells medicines and vaccines that originate in parent GSK's global range rather than from a large discovery programme of its own, so sales depend on doctors' prescriptions, on supply from the group and on drug price controls in India. GSK plc holds the controlling stake.
In one line: GSK's Indian pharma subsidiary.
Moat: narrow (brand, IP / patents). Access to GSK's global drug and vaccine portfolio with an established India prescriber base.
Headquarters: Mumbai, India · Founded: 1924 · Employees: 3,103
Size GlaxoSmithKline Pharmaceuticals (GLAXO.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $4.79B, the 218th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,638 on 18 Nov 2026.
Performance Over six months the shares gained 10.4%, against +10.5% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 12.1% over the last twelve months (peer median +11.3%); the operating margin is 32.9% (peer median 17.1%).
Valuation It trades at 37.3× forward earnings against a peer median of 21.5× (2nd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹41.6B | ₹38.2B | ₹37.5B | ₹34.5B | ₹32.5B |
| Revenue growth | — | +2% | +9% | +6% | — |
| Gross profit | ₹19.8B | ₹16.7B | ₹15.7B | ₹12.8B | ₹11.8B |
| EBITDA | ₹14.3B | ₹13.3B | ₹11.9B | ₹9.15B | ₹8.21B |
| Net income | ₹11.5B | ₹10.4B | ₹9.28B | ₹5.90B | ₹6.11B |
| Free cash flow | n/a | ₹9.64B | ₹13.9B | ₹6.44B | ₹5.03B |
| Capital expenditure | n/a | ₹553M | ₹230M | ₹312M | ₹440M |
| Total debt | ₹392M | ₹333M | ₹99.5M | ₹187M | ₹155M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% |
| Pfizer PFIZER.NS | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% |
| Sanofi India SANOFI.NS | $797M | 0% | -6% | 26% | 19.6× | 16.3% |
| Abbott India ABBOTINDIA.NS | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GLAXO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.7% | -1.3% | 7th highest of 21 |
| 6-month return | +10.4% | +10.5% | 10th lowest of 21 |
| Distance from 52-week high | -15.5% | -30.1% | 8th highest of 21 |
| Revenue growth (TTM) | +12.1% | +11.3% | 9th highest of 19 |
| Operating margin | 32.9% | 17.1% | 5th highest of 19 |
| Forward P/E | 37.3× | 21.5× | 2nd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 26.4% | 3.4% | most demanding of 17 |
| Growth delivered (Del g) | +5.5% | +12.5% | 6th lowest of 17 |
| Hurdle (Req g minus delivered) | +20.9 pp | -6.3 pp | most demanding of 17 |
| EV / EBITDA | 29.8× | 17.2× | 2nd most expensive of 10 |
| Net debt / EBITDA | -1.5× | -0.5× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |